Autonomix Medical Completes 1-for-21 Reverse Stock Split, Retains Massive Share Authorization

summarizeSummary

Autonomix Medical, Inc. has completed a 1-for-21 reverse stock split, reducing outstanding shares to approximately 542,000 while authorized shares remain at 500 million, creating significant potential for future dilution.

check_boxKey Events

• Reverse Stock Split Completed

  The company has completed a 1-for-21 reverse stock split, effective June 24, 2026, to increase its per-share price.

• Share Structure Impact

  Outstanding shares have been reduced from approximately 11.4 million to 542,000 post-split, while the number of authorized shares remains at 500 million.

• Significant Dilution Headroom

  With 500 million authorized shares and only 542,000 outstanding, the company has authorization to issue shares equivalent to over 92,000% of current outstanding shares, creating a substantial overhang.

• Nasdaq Listing Compliance

  This action is intended to help the company regain compliance with Nasdaq's minimum bid price requirement, following a prior delisting threat disclosed in a recent 10-K filing.

auto_awesomeAnalysis

Autonomix Medical, Inc. has formally completed its 1-for-21 reverse stock split, a critical action to regain compliance with Nasdaq's minimum bid price requirement following a prior delisting threat. While the split increases the per-share price, it does not alter the company's fundamental valuation. The most significant aspect of this filing is the resulting share structure: outstanding shares are now approximately 542,000, but the number of authorized shares remains at 500 million. This creates an extremely large headroom for future share issuances. If all authorized shares were issued, existing shareholders would face over 92,000% potential dilution, which could significantly pressure the stock price and raises concerns about future capital raises, especially given the company's previously reported going concern warning.